Bicara Therapeutics Inc (NASDAQ:BCAX) price on current trading day, fall -44.35% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $8.72.
A look at the stock’s price movement, the level at last check in today’s session was $15.66. Turning to its 52-week performance, $28.09 and $8.91 were the 52-week high and 52-week low respectively. Overall, BCAX moved -44.24% over the past month.
Bicara Therapeutics Inc’s market cap currently stands at around $475.28 million, with investors looking forward to this quarter’s earnings report slated for in June.
BCAX’s current price about -37.08% and -33.09% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 33.09, while 7-day volatility ratio is 4.82% and 5.71% in the 30-day chart. Further, Bicara Therapeutics Inc (BCAX) has a beta value of 0, and an average true range (ATR) of 1.95. Analysts have given the company’s stock an average 52-week price target of $48, forecast between a low of $48 and high of $48. Looking at the price targets, the low is -450.46% off recent price level in today’s trading while to achieve the yearly target high, it has to move -450.46%. Nonetheless, investors will most likely welcome a -450.46% jump to $48 which is the analysts’ median price.
If we refocus on Bicara Therapeutics Inc (NASDAQ:BCAX), historical trading data shows that trading volumes averaged 588.53K over the past 3 months. The company’s latest data on shares outstanding shows there are 54.53 million shares.
The 39.92% of Bicara Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 62.30% of the company’s shares. Current price change has pushed the stock -49.97% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the BCAX stock continues to rise going into the next quarter.
